These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 18787530)

  • 1. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma.
    Eichler HG; Pignatti F; Flamion B; Leufkens H; Breckenridge A
    Nat Rev Drug Discov; 2008 Oct; 7(10):818-26. PubMed ID: 18787530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of scientific evidence of risks and benefits in determining risk management policies for medications.
    Andrews E; Dombeck M
    Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):599-608. PubMed ID: 15362082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceuticals--strategic considerations in health reforms in Pakistan.
    Nishtar S
    J Pak Med Assoc; 2006 Dec; 56(12 Suppl 4):S100-11. PubMed ID: 17595837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical marketing practices: balancing public health and law enforcement interests; moving beyond regulation-through-litigation.
    Zalesky CD
    J Health Law; 2006; 39(2):235-64. PubMed ID: 17002233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
    Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
    Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis.
    Mussen F; Salek S; Walker S
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S2-S15. PubMed ID: 17546573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety assessment of new products developed by the pharmaceutical industry].
    Claude JR
    Ann Pharm Fr; 2001 Sep; 59(5):324-30. PubMed ID: 11787426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing therapeutic benefit and risk.
    Meyboom RH; Egberts AC
    Therapie; 1999; 54(1):29-34. PubMed ID: 10216419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drug adoption models: a review and assessment of future needs.
    Agrawal M; Calantone RJ
    Health Mark Q; 1995; 12(4):93-111. PubMed ID: 10143893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacy in the 90's: the modern process of drug registration].
    Pasotti V
    Boll Chim Farm; 1989; 128(7-8):248-52. PubMed ID: 2611010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quantitative approach to benefit-risk assessment of medicines - part 2: the practical application of a new model.
    Mussen F; Salek S; Walker S; Phillips L
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S16-41. PubMed ID: 17546574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotech drug market steadily expands.
    Lawrence S
    Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
    [No Abstract]   [Full Text] [Related]  

  • 14. Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.
    Leong J; McAuslane N; Walker S; Salek S
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):1004-12. PubMed ID: 23740622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
    Wright C; Schnoll S; Bernstein D
    Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical new product development: the increasing role of in-licensing.
    Edwards NV
    Anesthesiol Clin; 2008 Dec; 26(4):627-36, v. PubMed ID: 19041620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Similarity of biotechnology-derived drugs: regulatory framework and specificity].
    Prugnaud JL
    Ann Pharm Fr; 2008 Aug; 66(4):206-11. PubMed ID: 18847566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The identification of benefit in medical intervention: an overview and suggestions for process.
    Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
    Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hasty approval, more withdrawals.
    Prescrire Int; 2005 Aug; 14(78):144. PubMed ID: 16106597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk assessment of drugs, biologics and therapeutic devices: present and future issues.
    Centers for Education and Research on Therapeutics Risk Assessment Workshop
    Pharmacoepidemiol Drug Saf; 2003 Dec; 12(8):653-62. PubMed ID: 14762981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.